TD Waterhouse Canada’s Intellia Therapeutics NTLA Stock Holding History

TD Waterhouse Canada’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.84K	Hold	281	–	–	﹤0.01%	1988
2026 Q1	$3.72K	Buy	281 +81	+41%	+$1.03K	﹤0.01%	1964
2025 Q4	$1.8K	Hold	200	–	–	﹤0.01%	1829
2025 Q3	$3.75K	Hold	200	–	–	﹤0.01%	1740
2025 Q2	$1.98K	Hold	200	–	–	﹤0.01%	1733
2025 Q1	$1.33K	Hold	200	–	–	﹤0.01%	1722
2024 Q4	$2.33K	Hold	200	–	–	﹤0.01%	1689
2024 Q3	$3.84K	Hold	200	–	–	﹤0.01%	1543
2024 Q2	$4.49K	Hold	200	–	–	﹤0.01%	1514
2024 Q1	$5.02K	Hold	200	–	–	﹤0.01%	1536
2023 Q4	$5.9K	Hold	200	–	–	﹤0.01%	1351
2023 Q3	$5.88K	Hold	200	–	–	﹤0.01%	1331
2023 Q2	$8.15K	Hold	200	–	–	﹤0.01%	1287
2023 Q1	$7.42K	Hold	200	–	–	﹤0.01%	1291
2022 Q4	$6.93K	Hold	200	–	–	﹤0.01%	1286
2022 Q3	$11.2K	Sell	200 -75	-27%	-$4.65K	﹤0.01%	1218
2022 Q2	$14.9K	Hold	275	–	–	﹤0.01%	1167
2022 Q1	$20.9K	Sell	275 -75	-21%	-$6.35K	﹤0.01%	1172
2021 Q4	$39.7K	Buy	+350	New	+$43.8K	﹤0.01%	1054

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

TD Waterhouse Canada's NTLA Position: Q2 2026 in Review

TD Waterhouse Canada held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 281 shares worth $4.84K. The position accounts for ﹤0.01% of the portfolio, ranked #1988.

TD Waterhouse Canada first reported a position in NTLA in Q4 2021 and has held it in 19 quarters since. The position peaked at $39.7K in Q4 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

TD Waterhouse Canada held 281 shares of Intellia Therapeutics worth $4.84K as of Q2 2026.
TD Waterhouse Canada left its Intellia Therapeutics share count unchanged in Q2 2026.
Intellia Therapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #1988 holding.
TD Waterhouse Canada first reported a position in Intellia Therapeutics in Q4 2021 and has held it in 19 quarters since.
TD Waterhouse Canada's Intellia Therapeutics position peaked at $39.7K in Q4 2021.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.